Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection

Por Chakraborty, Abhijit, Roy, Sandip, Loeffler, Juergen, Chaves, Ricardo L.
Publicado em 2009

A potential role for daptomycin in enterococcal infections: what is the evidence?

Por Cantón, Rafael, Ruiz-Garbajosa, Patricia, Chaves, Ricardo L., Johnson, Alan P.
Publicado em 2010

Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy

Por Xu, Xiaoying, Khadzhynov, Dmytro, Peters, Harm, Chaves, Ricardo L., Hamed, Kamal, Levi, Micha, Corti, Natascia
Publicado no Br J Clin Pharmacol (2016)

Clinical experience with daptomycin in Europe: the first 2.5 years

Por Gonzalez-Ruiz, Armando, Beiras-Fernandez, Andres, Lehmkuhl, Hans, Seaton, R. Andrew, Loeffler, Juergen, Chaves, Ricardo L.
Publicado em 2011

High correlation of VAS pain scores after 2 and 6 weeks of treatment with VAS pain scores at 12 weeks in randomised controlled trials in rheumatoid arthritis and osteoarthritis: me...

Por Karabis, Andreas, Nikolakopoulos, Stavros, Pandhi, Shaloo, Papadimitropoulou, Katerina, Nixon, Richard, Chaves, Ricardo L., Moore, R. Andrew
Publicado no Arthritis Res Ther (2016)

Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORE(SM) database

Por Seaton, R. Andrew, Malizos, Konstantinos N., Viale, Pierluigi, Gargalianos-Kakolyris, Panagiotis, Santantonio, Teresa, Petrelli, Enzo, Pathan, Rashidkhan, Heep, Markus, Chaves, Ricardo L.
Publicado em 2013

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomi...

Por Cooper, David A., Cordery, Damien V., Zajdenverg, Roberto, Ruxrungtham, Kiat, Arastéh, Keikawus, Bergmann, Frank, Neto, José L. de Andrade, Scherer, Joseph, Chaves, Ricardo L., Robinson, Patrick
Publicado no PLoS One (2016)